Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note issued to investors on Tuesday. The firm issued a buy rating and a $580.00 target price on the pharmaceutical company’s stock.

VRTX has been the subject of several other reports. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Royal Bank Of Canada dropped their price objective on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. UBS Group upped their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Morgan Stanley reiterated an “overweight” rating and issued a $570.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, HC Wainwright increased their price target on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research note on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $548.73.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $460.87 on Tuesday. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $519.68. The stock has a market cap of $117.07 billion, a price-to-earnings ratio of 30.06 and a beta of 0.31. The business has a fifty day moving average of $467.50 and a 200-day moving average of $435.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.98 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Jonathan Biller sold 945 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $459,600.75. Following the sale, the executive vice president directly owned 13,659 shares in the company, valued at $6,643,054.65. This trade represents a 6.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Duncan Mckechnie sold 4,910 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 91,156 shares of company stock valued at $42,845,497 over the last three months. Insiders own 0.20% of the company’s stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Earned Wealth Advisors LLC increased its holdings in Vertex Pharmaceuticals by 3.3% in the fourth quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock valued at $295,000 after buying an additional 21 shares in the last quarter. Confluence Wealth Services Inc. lifted its stake in Vertex Pharmaceuticals by 4.0% during the fourth quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after buying an additional 21 shares in the last quarter. Williams Jones Wealth Management LLC. grew its position in shares of Vertex Pharmaceuticals by 1.9% in the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock valued at $524,000 after purchasing an additional 21 shares during the last quarter. Childress Capital Advisors LLC boosted its stake in Vertex Pharmaceuticals by 3.1% in the fourth quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company’s stock worth $331,000 after purchasing an additional 22 shares in the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in shares of Vertex Pharmaceuticals by 0.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 5,026 shares of the pharmaceutical company’s stock worth $2,279,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER interim results met the primary and all secondary endpoints — Vertex reported strong Week 36 data showing povetacicept produced meaningful effects in adults with IgAN; the company described the readout as positive and the market reacted with after-hours buying. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Company and press reports say the data are strong enough that Vertex plans an FDA filing (reportedly by March) for povetacicept, and headlines emphasized a late-session/share pop — a clear near-term catalyst for upside if regulators agree on the path. Vertex (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results
• Positive Sentiment: Analysts reacted quickly: HC Wainwright raised its price target to $641 and kept a Buy rating; BMO Capital and William Blair reiterated Buy ratings with elevated targets (~$600 from BMO cited), reflecting expectations that povetacicept could be “best-in-class” in IgAN and add upside beyond Vertex’s cystic fibrosis cash flows. HC Wainwright price-target raise BMO / analyst coverage
• Neutral Sentiment: The RAINIER result cited is an interim analysis of an ongoing Phase 3 trial — strong interim data are encouraging but full trial readouts, regulatory review, and long-term safety/efficacy data remain to be confirmed. Investors should note the typical regulatory and commercialization execution risks. Yahoo Finance: Vertex interim analysis
• Negative Sentiment: Separately, Vertex’s most recent quarterly report showed a tiny EPS miss (reported 5.03 vs. 5.05 consensus) and, while revenue grew year-over-year, investors should weigh near-term valuation versus long-term pipeline upside. This older earnings miss could temper upside if pipeline approvals face delays. MarketBeat: VRTX profile / recent results

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.